13 july 2018 daily equity reports

1. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. CapitalStars Investment Adviser: SEBI Registration Number: INA000001647 DAILY EQUITY REPORT 13THJULY 2018 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

2. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report INDIAN FACE INDIAN MARKET CLOSE PREVIOUS ! 36548.41 INDIAN EQUITY BENCHMARK:- Equity benchmarks have ended the session on a strong note, with the Sensex closing over 280 points higher, while the Nifty managed to close above 11,000-mark. The Sensex is up 282.48 points or 0.78% at 36548.41, while the Nifty is up 68.50 points or 11023.20 ASIAN MARKET CLOSE PREVIOUS 0.63% at 11016.80. The market breadth is negative as 1151 NIKKEI 22187.96 shares advanced, against a decline of 1475 shares, while 177 28480.83 shares were unchanged.Reliance Industries, Wipro and BPCL 2280.62 are the top gainers, while Vedanta, Infosys and UPL have lost SECTORIAL INDICES the most on both the indices. GLOBAL FACE CLOSE CHANGE (%) 11269.70 0.56 ! 0.39 Asian Market - Asian markets finished broadly higher today with shares in China leading the region. The Shanghai Composite is up 2.16% while Japan's Nikkei 225 is up 1.17% and Hong Kong's Hang Seng is up 0.60%. -0.51 0.44 ! 27026.55 0.78 U.S. Market -Asian markets gain, with China leading the advance after recent trade shock ! European markets - European markets are higher today with CLOSE CHANGE (%) 1080.90 4.05 shares in London leading the region. The FTSE 100 is up BPCL 2.89 0.78% while France's CAC 40 is up 0.64% and Germany's DAX is up 0.58%. 2417.20 2.62 WIPRO 2.46 TOP LOSERS CLOSE CHANGE (%) UPL -4.21 VEDL -2.87 BAJAJAUTO 3097.15 -2.04 1295.00 -1.93 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

3. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report NIFTY SPOT MARKET MOVERS UPSIDE TREND STRATEGY SCRIPT CLOSE (%) 11.71 BEARISH YESBANK 374.80 1082.20 9.31 P R1 R2 11112 RESISTANCE R1-11100 R2-11240 R3 11191 RELIANCE 10875 10954 10988 11033 11067 1005.30 8.63 HCLTECH SUPPORT S1-10700 S2-10640 7.56 CLOSE (%) -8.85 -8.62 -7.36 VEDANTA -7.16 BANK NIFTY FUTURE NET (CR.) TREND BULLISH 4962.89 4326.62 DII 3728.65 S3 S1 P R1 R2 R3 26447 26861 27007 27141 NSE TOTALS SUPPORT S1-26600 S2-26400 RESISTANCE ADVANCE BANK NIFTY BANK NIFTY 8 4 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

4. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report MARKET TALKS ! Tata Power to develop 250 MW Solar Project in Karnataka Tata Power, India’s largest integrated power company, announced that Tata Power Renewable Energy Limited (TPREL), the Company’s wholly-owned subsidiary, has received a Letter of Award from Karnataka Renewable Energy Development Limited (KREDL) to develop 250 MW (50 MW x 5 Nos) of solar projects located in state’s Tumkur district at Karnataka. ! SEBI mulls ‘Snapchat model’ to facilitate listing of Indian startups A SEBI-appointed committee has discussed the proposal of allowing companies to sell shares with differential voting rights at its first meeting held last week ! Gold falls on weak global cues, lacklustre demand Gold shed Rs 140 to Rs 31,210 per ten gram today in line with a subdued trend overseas and muted demand from local jewellers. Silver followed suit and slipped by Rs 470 to Rs 40,030 per kg owing to reduced offtake by industrial units and coin makers.. ! Ajanta Pharma gets tentative approval to gRanexa Ajanta Pharma has received tentative USFDA approval for Ranolazine, the generic version of Gilead Sciences' brand name drug Ranexa. Gilead Sciences will lose the exclusive patents on Ranexa in 2019. Lupin, meanwhile, has received final approval to manufacture the generic version of Ranexa in the US market. Lupin is likely to be the first applicant for this drug in the US market. Ranexa's sales in the US markets generated $717mn in 2017, up 6% yoy from $677mn in 2016. Teva and Aurobindo Pharma also have tentative approval for this drug. Cipla acquires South African company Mirren Pty ! Cipla, through its South African subsidiary, Medpro South Africa, has acquired 100% stake in another South African company, Mirren Pty, for Rs228cr (450mn South African Rand). Mirren is a 35-year-old South African OTC pharma company. It has a well-established brand portfolio such as Bronco cough syrup, Coryx, Tensopyn, and Ultimag. Mirren’s FY18 revenue grew by 23.7% yoy to 152mn Rand (Rs77.3cr). Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

5. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. DISCLAIMER The information and views in this report & all the service we provide are believed to be reliable, but we do not accept any responsibility for errors of fact or opinion. Investors have the right to choose the product/s that suits them the most. Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and up on sources that we consider reliable. This material is for personal information and based upon it & takes no responsibility. The information given herein should be treated as only factor, while making investment decision. The report does not provide individually tailor-made investment advice. My research recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. Capitalstars shall not be responsible for any transaction conducted based on the information given in this report, which is in violation of rules and regulations of regulators. The price projections shown are not necessarily indicative of future price performance. The information herein, together with all estimates and forecasts, can change without notice. It is understood that anyone who is browsing through the site has done so at his free will and does not read any views expressed as a recommendation for which either the site or its owners or anyone can be held responsible for. Investment & Trading in Securities Markets are always subjected to market risk. Capitalstars Financial Research Private Ltd., Reserves all Rights. INVESTMENT AND TRADING IN SECURITIES MARKET IS ALWAYS SUBJECTED TO MARKET RISK. Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

6. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. CapitalStars Financial Research Private Limited is an advisory company incepted with a vision of providing fair and accurate trading and investment calls in share and commodity market.we specialize in thorough fundamental and technical research analysis in equity and commodity market to provide best equity and commodity tips to traders and investors.we provide intraday as well as delivery stock tips in NSE and BSEand commodity tips in MCX and NCDEX. Visit us : www.capitalstars.com Call us : 9977499927 7440449744 Our services : Mcx Tips Intraday Stock Tips Finacial Advisory Company Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

7. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. BRANCH OFFICE Capitalstars Financial Research Private Limited PLOT NO.32, MECHANIC NAGAR EXTENSION,IDA SCHEME NO.54,VIJAYNAGAR INDORE REGISTERED OFFICE PLOT NO.12, SCHEME NO.78 PART-2, VIJAY NAGAR, INDORE Email:-backoffice@capiltalstars.in Report Is Checked by Investment Advisor: Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.